| Trial ID: | L0889 |
| Source ID: | NTR4913
|
| Associated Drug: |
Eubacterium hallii
|
| Title: |
Dosefinding trial studying effect of 4 weeks Intervention on safety and efficacy in males with Metabolic syndrome with oral Eubacterium hallii
|
| Acronym: |
--
|
| Status: |
Not Recruiting
|
| Study Results: |
No Results Available
|
| Results: |
--
|
| Conditions: |
metabolic syndrome, obesity, insulin resistance, NAFLD
|
| Interventions: |
increasing daily dosages of eubacterium hallii (10e6, 10e8 and 10e10 cells/ml) for 4 weeks in male subjects with metabolic syndrome
|
| Outcome Measures: |
- Safety (plasma biochemistry eg hepatic /inflammatory/cholesterol markers) and <br>increase in fecal E. hallii levels upon increasing dosages of daily oral Ehallii treatment<br>- Insulin sensitivity as assessed by hyperinsulinemic clamp using stable isotope infusion) at baseline and 4 weeks upon increasing dosages of daily oral Ehallii treatment<br>- Effect on daily dietary intake and bowel habits (monitored using standardized questionnaires)
|
| Sponsor/Collaborators: |
--
|
| Gender: |
--
|
| Age: |
--
|
| Phases: |
Not applicable
|
| Enrollment: |
--
|
| Study Type: |
--
|
| Study Designs: |
--
|
| Start Date: |
--
|
| Completion Date: |
--
|
| Results First Posted: |
--
|
| Last Update Posted: |
--
|
| Locations: |
--
|
| URL: |
--
|
